iWisdom

iWisdom is wrapping up a busy year on a high. Our latest article in the Life Sciences Review marks the end of this year, with more exciting news lined up for 2025. Throughout the year, iWisdom and our partners have seen remarkable growth through the successful implementation of our impactful 3-part module: commercialize, advise, and invest. This growth has been fueled by tapping into the expertise and networks of our seasoned team. For more insights, delve into the article. Wishing you all seasons greetings and a Happy New Year filled with success. #iWisdom #Commercialise #Invest #Advice https://lnkd.in/erjnUwnQ

iWisdom is proud to collaborate with Professor Dan Peer, recently inducted as a Fellow of the United States National Academy of Inventors (NAI). This distinguished accolade celebrates visionaries whose inventions drive positive change in society, elevate economic growth, and enhance overall well-being. Professor Peer stands at the forefront of RNA-based molecular therapies, spearheading breakthroughs in combating various ailments such as cancer and genetic disorders. His pioneering work in systemic mRNA and RNA-based vaccine delivery, along with innovative gene-targeting methodologies, showcases his unwavering commitment to advancing healthcare solutions. With a remarkable portfolio boasting over 145 patents, Professor Peer has also been instrumental in establishing successful ventures like NeoVac, a valued partner of iWisdom. The NAI Fellowship underscores his exceptional contributions to scientific advancement, innovation, and the betterment of communities. #NeoVac #TAU #mRNA #LNPs

Reflections from the UK Early Stage Investment Summit 🌍   We had the great opportunity to attend the UK Early Stage Investment Summit, where we gained valuable insights into scaling ventures and navigating the investment landscape. Key takeaways include: Green Investments: -The belief that profitability and sustainability are at odds is fading. Decarbonization is increasingly seen as a strong driver of innovation and returns. Exciting opportunities, such as circular carbon capture, highlight this shift, though they require strategic planning and partnerships.   International Investments : - In the UK, the majority of £15M+ investments come from overseas investors. However, these investments are only possible if founders adopt a global strategy and funding plan from day one. - Success depends on demonstrating scalability, navigating international markets, and presenting a clear pathway to ROI. Investors are drawn to companies with leadership teams that balance technical expertise with commercial acumen.   Public-Private Partnerships: - We discussed how collaborations between governments and private investors are essential for funding early-stage innovation. - Programs providing non-dilutive funding options, such as venture debt, help founders de-risk projects and prepare for commercialization. - These partnerships are driving growth in key sectors like clean energy, life sciences, and deep tech by blending public funding with private expertise.   UK’s Unique Edge: - Despite economic uncertainty, with the Bank of England warning of a temporary rise in inflation and a stagnating GDP growth, the UK remains Europe’s early-stage biotech leader.   The summit emphasized the importance of aligning funding strategies with global ambitions and the UK continues to be an exciting hub for transformative ventures. 🚀   #UKInvestmentSummit #GlobalPerspective #BiotechLeadership #Decarbonization #Innovation #FundingStrategy

🚨 Exciting Collaboration Announcement! 🚨 We’re thrilled to announce that iWisdom has joined forces with Y Innovations in a transformative partnership to accelerate biopharma innovation. Together, we aim to create thriving innovation hubs, spanning discovery to commercialization, in emerging regions. 🌍 📌 What This Collaboration Means: Strategic Focus: The development and commercialization of three groundbreaking assets in gene therapy and delivery. Uniting Strengths: Y Innovations’ expertise in early-stage development and financing meets iWisdom’s prowess in commercialization and global market access. A Shared Vision: Fast-tracking critical therapies, building essential infrastructure, and positioning emerging regions as global leaders in biopharma innovation. 💬 Leadership Perspectives: "Partnering with Y Innovations, a powerhouse with an impressive track record in biopharma innovation, takes this vision to new heights. Together, we’re building a stronger, more impactful gateway to address unmet regional needs," said Ishil K. Ozturk, Founder & Managing Director of iWisdom. "With Y Innovations’ early-stage expertise and iWisdom’s unmatched commercialization capabilities, this collaboration is set to fast-track the journey from discovery to delivery," added Megan Y., Founder & CEO of Y Innovations Group. We’re excited to enhance partnerships with stakeholders, driving impactful outcomes while empowering emerging regions to play a vital role in global biopharma innovation. #Collaboration #BiopharmaInnovation #EmergingRegions #GeneTherapy #GlobalPartnership #iWisdom #YInnovations

🚨 Exciting Collaboration Announcement! 🚨 We’re thrilled to announce that iWisdom has joined forces with Y Innovations in a transformative partnership to accelerate biopharma innovation. Together, we aim to create thriving innovation hubs, spanning discovery to commercialization, in emerging regions. 🌍 📌 What This Collaboration Means: Strategic Focus: The development and commercialization of three groundbreaking assets in gene therapy and delivery. Uniting Strengths: Y Innovations’ expertise in early-stage development and financing meets iWisdom’s prowess in commercialization and global market access. A Shared Vision: Fast-tracking critical therapies, building essential infrastructure, and positioning emerging regions as global leaders in biopharma innovation. 💬 Leadership Perspectives: "Partnering with Y Innovations, a powerhouse with an impressive track record in biopharma innovation, takes this vision to new heights. Together, we’re building a stronger, more impactful gateway to address unmet regional needs," said Ishil K. Ozturk, Founder & Managing Director of iWisdom. "With Y Innovations’ early-stage expertise and iWisdom’s unmatched commercialization capabilities, this collaboration is set to fast-track the journey from discovery to delivery," added Megan Y., Founder & CEO of Y Innovations Group. We’re excited to enhance partnerships with stakeholders, driving impactful outcomes while empowering emerging regions to play a vital role in global biopharma innovation. #Collaboration #BiopharmaInnovation #EmergingRegions #GeneTherapy #GlobalPartnership #iWisdom #YInnovations

🌍 At iWisdom, sustainability is at the heart of everything we do. We're thrilled to announce our future collaboration with DasDas on an exciting project: the repurposing of the iconic Shoe Lane Library turning it into a sustainable arts and culture center that supports social, cultural, and economic development ! 📚✨ This initiative aligns with our vision of creating meaningful impact through innovative partnerships. Stay tuned for more updates as we continue our journey towards a more sustainable future. 🌱 #Sustainability #Innovation #Partnerships #iWisdom

𝐃𝐮𝐛𝐚𝐢’𝐬 𝐀𝐦𝐛𝐢𝐭𝐢𝐨𝐧 𝐭𝐨 𝐋𝐞𝐚𝐝 𝐆𝐥𝐨𝐛𝐚𝐥 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐃𝐮𝐛𝐚𝐢 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐅𝐨𝐫𝐮𝐦 (𝐋𝐨𝐧𝐝𝐨𝐧) 𝐚𝐧𝐝 𝐚 𝐫𝐞𝐜𝐞𝐧𝐭 𝐯𝐢𝐬𝐢𝐭 𝐭𝐨 𝐃𝐮𝐛𝐚𝐢 🚀🌍 Recently, I had the privilege of attending the 𝐃𝐮𝐛𝐚𝐢 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐅𝐨𝐫𝐮𝐦 in London, where the Dubai government showcased its ambitious D33 Strategy, aiming to double the emirate's GDP by 2033. This aligns with Dubai’s vision to become a global leader in key sectors like Logistics, Manufacturing, Financial Services, and Tourism. It’s a bold strategy that’s already gaining traction with impressive developments in biotech and life sciences, which I’m excited to be a part of. Key Highlights from the Forum: 🔑 Logistics: Dubai continues to lead as a global logistics hub with its state-of-the-art infrastructure like Dubai Airport and Jebel Ali Freeport. 🔑 Manufacturing: A key area of focus, with plans to grow the sector in high technology sectors. 🔑 Financial Services: Dubai stands as the region’s largest financial market, hosting almost 200 venture capital firms, over 60 hedge funds, and over 200 fintech startups. It’s a hub attracting significant FDI, even as global FDI declined last year. 🔑 Tourism: Dubai remains a global tourism powerhouse, hosting one of the world’s largest startup meeting, Expand North Star with 1800 startups and 1200 investors. The overarching message was clear: “𝘙𝘦𝘥 𝘤𝘢𝘳𝘱𝘦𝘵, 𝘯𝘰𝘵 𝘳𝘦𝘥 𝘵𝘢𝘱𝘦”. Dubai is not only making strides in creating a favourable investment climate but is also positioning itself as a gateway to the region, and acting as a bridge between East and West. The city offers a safe and familiar place for business, with policies designed to encourage investment in sustainability, AI, finance, and life sciences. At iWisdom, we are excited about the opportunities to help Dubai become a global leader in biotech innovation and commercialization. We recently had very productive discussions with @Dr. Marwan Abdulaziz Janahi at @𝐃𝐮𝐛𝐚𝐢 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐏𝐚𝐫𝐤, exploring potential partnerships with local authorities and biotech organizations to accelerate commercialization opportunities and secure investment. These conversations align perfectly with Dubai's D33 Strategy, which aims to foster innovation and collaboration across industries to position the emirate as a hub for cutting-edge science development. The future of biotech is bright, and we are proud to be part of this transformative journey in Dubai! Together with the ambitious D33 Strategy, we’re excited to help position Dubai as a global leader in innovation and commercialization—especially in the life sciences and biotech sectors. Looking forward to continued collaboration and growth in the months ahead! hashtag #D33Strategy#Dubai#Innovation#Biotech#LifeSciences#Investment#Commercialization#Manufacturing#Logistics#Sustainability#AI#Partnerships#DubaiSciencePark#iWisdom#MENA#DubaiBusinessForum

To exciting times ahead with Y Innovations!

🌍 This week’s Riyadh Global Medical Biotechnology Summit reinforced our observations about the rapid advancements in Saudi Arabia’s biotech landscape. I was joined by our trusted Middle East advisor, Adriana Guerrero, who brought valuable perspectives by drawing insightful parallels with the Energy sector. 🚀 The focus was all about accelerating the pace of innovation and commercialization, with partnerships taking center stage. It's inspiring to see the strong support Saudi Arabia is receiving from leading global institutions and industry players. The recognition that, following the US and Europe, KSA is poised to become the third major hub for biotechnology renews our confidence in the region’s potential. Selected slides attached from the Saudi NIH and the JP Morgan session. #Biotechnology #Innovation #Commercialization #RiyadhBiomedicalSummit #SaudiArabia #GlobalPartnerships

𝗥𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗼𝗻 𝗞𝗦𝗔’𝘀 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗝𝗼𝘂𝗿𝗻𝗲𝘆 After an intensive schedule filled with meetings with entrepreneurs, academic institutions, ministries, and both private and government-funded companies, a common ambition emerged: achieving tangible outcomes in driving and retaining IP in biotech. The mindset has shifted dramatically moving beyond simply catching up with the most advanced BioTech hubs in the world to a more 𝑜𝑢𝑡𝑐𝑜𝑚𝑒-𝑑𝑟𝑖𝑣𝑒𝑛 𝑎𝑝𝑝𝑟𝑜𝑎𝑐ℎ, 𝑚𝑎𝑟𝑘𝑒𝑑 𝑏𝑦 𝐾𝑃𝐼𝑠 𝑓𝑜𝑐𝑢𝑠𝑒𝑑 𝑜𝑛 𝑐𝑜𝑚𝑚𝑒𝑟𝑐𝑖𝑎𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑎𝑛𝑑 𝑎 𝑟𝑜𝑏𝑢𝑠𝑡 𝑖𝑛𝑓𝑟𝑎𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒 designed to fuel and sustain that ambition. This shift is now embedded in the thinking of not only researchers but also private investors. In regions where this infrastructure already exists, it’s easy to take it for granted and overlook the long journey that made it possible—years of dedication, numerous failures overshadowing successes, managing complex public-private stakeholder dynamics, and navigating the unpredictable nature of scientific discovery. The art of risk diversification and fund optimization, coupled with capturing opportunities, becomes essential. These elements form the backbone of a sustainable biotech commercialization ecosystem that generates IP rather than merely acquiring it. 𝑾𝒉𝒂𝒕 𝒔𝒕𝒐𝒐𝒅 𝒐𝒖𝒕 𝒅𝒖𝒓𝒊𝒏𝒈 𝒆𝒏𝒈𝒂𝒈𝒆𝒎𝒆𝒏𝒕𝒔 was the collective acknowledgment among stakeholders of the challenges ahead, paired with a clear awareness that this is uncharted territory. The resolve for significant support and the collaborative spirit to accelerate progress were palpable. Most importantly, the approach reflected the lessons learned over the past seven years—understanding what hasn’t worked and what needs to change for success. This deliberate, reflective attitude is what will bridge the gap between ambition and achievement. 👍 𝑲𝒆𝒚 𝑯𝒊𝒈𝒉𝒍𝒊𝒈𝒉𝒕𝒔: 1- 𝐺𝑟𝑜𝑤𝑡ℎ 𝑀𝑖𝑛𝑑𝑠𝑒𝑡: A shift towards embracing continuous learning, adapting strategies, and striving for improvement at every level. 2- 𝐹𝑙𝑒𝑥𝑖𝑏𝑙𝑒 𝑇ℎ𝑖𝑛𝑘𝑖𝑛𝑔: An openness to novel solutions and innovative approaches that meet the unique challenges of this journey. 3- 𝐸𝑑𝑢𝑐𝑎𝑡𝑒𝑑 𝑎𝑛𝑑 𝐷𝑟𝑖𝑣𝑒𝑛 𝐶𝑢𝑙𝑡𝑢𝑟𝑒: A well-educated workforce willing to put in the effort to carve out an authentic space and make meaningful contributions. 👏 A huge shout-out to all the teams diligently applying this new mindset daily—from research and startups to commercialization efforts, regulatory setups, clinical pathways, and more. Persistence is key, and it will be the driving force behind the Kingdom’s emergence as a leader in biopharma IP and innovation aligned with the National Biotechnology Strategy. #Biotech #Commercialization #Innovation #SaudiArabia #IPDevelopment #Collaboration